Holen Sie sich die Stockscreener-App
28.17
2.78%
0.7875
Schlusskurs vom Vortag:
$27.38
Offen:
$27.515
24-Stunden-Volumen:
249.10K
Relative Volume:
0.30
Marktkapitalisierung:
$2.66B
Einnahmen:
$4.72M
Nettoeinkommen (Verlust:
$-277.91M
KGV:
-7.5516
EPS:
-3.73
Netto-Cashflow:
$-203.56M
1W Leistung:
-3.76%
1M Leistung:
-11.87%
6M Leistung:
-20.08%
1J Leistung:
-43.23%
1-Tages-Spanne:
$27.52
$28.59
1-Wochen-Bereich:
$25.83
$29.18
52-Wochen-Spanne:
$24.10
$62.53
Crinetics Pharmaceuticals Inc Stock (CRNX) Company Profile
Firmenname
Crinetics Pharmaceuticals Inc
Sektor
Branche
Telefon
858-450-6464
Adresse
6055 LUSK BLVD., SAN DIEGO, CA
Vergleichen Sie CRNX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CRNX
Crinetics Pharmaceuticals Inc
|
28.21 | 2.52B | 4.72M | -277.91M | -203.56M | -3.73 |
|
VRTX
Vertex Pharmaceuticals Inc
|
384.62 | 93.98B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
559.69 | 59.67B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
432.10 | 57.53B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
642.82 | 40.50B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
289.24 | 34.26B | 3.81B | -644.79M | -669.77M | -6.24 |
Crinetics Pharmaceuticals Inc Stock (CRNX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-07-10 | Eingeleitet | Goldman | Neutral |
| 2025-03-25 | Eingeleitet | Stifel | Buy |
| 2025-02-11 | Eingeleitet | TD Cowen | Buy |
| 2025-02-04 | Eingeleitet | Wolfe Research | Peer Perform |
| 2025-01-22 | Hochstufung | Jefferies | Hold → Buy |
| 2024-03-06 | Eingeleitet | Citigroup | Buy |
| 2024-01-16 | Eingeleitet | Morgan Stanley | Overweight |
| 2023-12-21 | Eingeleitet | Jefferies | Hold |
| 2023-11-20 | Fortgesetzt | JP Morgan | Overweight |
| 2023-10-24 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2023-08-31 | Eingeleitet | Oppenheimer | Outperform |
| 2023-04-24 | Eingeleitet | Piper Sandler | Overweight |
| 2023-03-30 | Eingeleitet | Robert W. Baird | Outperform |
| 2021-11-30 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2021-11-23 | Eingeleitet | Evercore ISI | Outperform |
| 2021-06-18 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2019-12-23 | Eingeleitet | ROTH Capital | Buy |
| 2019-02-14 | Eingeleitet | H.C. Wainwright | Buy |
| 2018-08-13 | Eingeleitet | JP Morgan | Neutral |
| 2018-08-13 | Eingeleitet | Leerink Partners | Outperform |
| 2018-08-13 | Eingeleitet | Piper Jaffray | Overweight |
Alle ansehen
Crinetics Pharmaceuticals Inc Aktie (CRNX) Neueste Nachrichten
Crinetics Pharmaceuticals Announces August 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Crinetics Expands Team with 27 New Hires, Grants $2M+ in Equity Compensation Package - Stock Titan
Crinetics stock price target lowered to $86 by Citizens JMP on launch outlook - Investing.com Canada
Crinetics Pharmaceuticals Inc's Q2 2025 Earnings Call Highlights: Strategic Advancements, Financial Resilience Amid Rising Costs. - AInvest
Crinetics Pharmaceuticals' Q2 2025 Earnings: Financial Vulnerability and Clinical Dependencies Amid Pipeline Advancements - AInvest
Investors Might Be Losing Patience for Crinetics Pharmaceuticals' (NASDAQ:CRNX) Increasing Losses, as Stock Sheds 3.6% Over the Past Week - 富途牛牛
Crinetics Pharmaceuticals, Inc. (CRNX) Reports Q2 Loss, Lags Revenue Estimates - MSN
Crinetics Pharmaceuticals: A Pipeline-Driven Inflection Point in Endocrine Therapeutics - AInvest
Crinetics 2025 Q2 Earnings Widening Losses Despite Revenue Surge - AInvest
How to read the order book for Crinetics Pharmaceuticals Inc.Free AI Trading Suggestions With Accuracy Focus - Newser
Transcript : Crinetics Pharmaceuticals, Inc., Q2 2025 Earnings Call, Aug 07, 2025 - MarketScreener
Crinetics Pharmaceuticals (NASDAQ:CRNX) Is In A Good Position To Deliver On Growth Plans - Yahoo Finance
Stifel lowers Crinetics stock price target to $58 from $60, keeps Buy rating - Investing.com Canada
Earnings call transcript: Crinetics Pharmaceuticals Q2 2025 results miss EPS forecast - Investing.com
Crinetics Pharmaceuticals Inc. (CRNX) Shares Soar 11.91% on 150% Revenue Surge - AInvest
Crinetics Pharmaceuticals Q2 Earnings: Revenue Rises, Shares Up - AInvest
Crinetics Pharmaceuticals Q2 Loss Widens, Revenue Rises; Shares up Pre-Bell - MarketScreener
Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Shares Sold by Zurcher Kantonalbank Zurich Cantonalbank - Defense World
Crinetics Pharmaceuticals Inc (CRNX) Q2 2025 Earnings Call Highlights: Strategic Advancements ... By GuruFocus - Investing.com Canada
Crinetics Pharmaceuticals Inc (CRNX) Q2 2025 Earnings Call Highl - GuruFocus
Will breakout in Crinetics Pharmaceuticals Inc. lead to full recoveryRisk Adjusted Trade Signal Screening Tool - Newser
Decoding Crinetics Pharmaceuticals Inc (CRNX): A Strategic SWOT Insight - GuruFocus
Crinetics Pharmaceuticals: Promising Outlook with Anticipated Approval of Palsonify and Strategic Market Launch - TipRanks
Crinetics Pharmaceuticals Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Crinetics reports Q2 EPS ($1.23), consensus ($1.10) - TipRanks
Why Crinetics Pharmaceuticals Inc. stock attracts strong analyst attentionSmart Risk Entry Zone Technical Analysis - Newser
Crinetics Pharma earnings missed by $0.13, revenue topped estimates - Investing.com Canada
Crinetics Q2: $1.2B cash, PDUFA date for PALSONIFY, atumelnant progress. - AInvest
Crinetics Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update | CRNX Stock News - GuruFocus
Crinetics Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update - The Manila Times
Crinetics Earnings: $1.2B War Chest Powers PALSONIFY Launch, FDA Decision Looms in September - Stock Titan
Crinetics Pharmaceuticals Q2 2025 Earnings Call Transcript - MarketBeat
Crinetics CRNX Q2 2025 Earnings Preview Downside Expected on Analyst EPS Downgrades - AInvest
Crinetics Pharmaceuticals, Inc. (CRNX)’ Oral Acromegaly Drug Nears FDA Decision After Strong Phase 3 Data - MSN
What are the technical indicators suggesting about Crinetics Pharmaceuticals Inc.Dynamic investment growth - Jammu Links News
Is it the right time to buy Crinetics Pharmaceuticals Inc. stockFastest-growing stock picks - Jammu Links News
What are analysts’ price targets for Crinetics Pharmaceuticals Inc. in the next 12 monthsStay informed with daily expert analysis - Jammu Links News
What institutional investors are buying Crinetics Pharmaceuticals Inc. stockFree Stock Movement Tracking - Jammu Links News
What is the risk reward ratio of investing in Crinetics Pharmaceuticals Inc. stockOver 200% growth - Jammu Links News
How strong is Crinetics Pharmaceuticals Inc. company’s balance sheetGet timely market insights for better trades - Jammu Links News
Real time alert setup for Crinetics Pharmaceuticals Inc. performanceConsistent Gain Plan with AI Support - Newser
When is Crinetics Pharmaceuticals Inc. stock expected to show significant growthInvest smarter with daily trading signals - Jammu Links News
Does Crinetics Pharmaceuticals Inc. stock perform well during market downturnsGet daily updates on market movers and shakers - Jammu Links News
Fibonacci Support Holding Strong in Crinetics Pharmaceuticals Inc.Trade Timing Strategy With Technical Data Explained - metal.it
Are Bears Losing Grip on Crinetics Pharmaceuticals Inc.Real Time Trade Opportunity Alerts Monitor Market Surges - metal.it
Earnings Preview: Crinetics Pharmaceuticals, Inc. (CRNX) Q2 Earnings Expected to Decline - Yahoo Finance
11 Best Future Stocks to Buy Now - Insider Monkey
What makes Crinetics Pharmaceuticals Inc. stock price move sharplyCapital Preserving Trade Plan Templates Shared - metal.it
Can Crinetics Pharmaceuticals Inc. Bounce Back From Weekly LowSmart Investment Tips Gaining Popularity Among Analysts - metal.it
Analyzing net buyer seller activity in Crinetics Pharmaceuticals Inc.Steady Return Plan Based on Data Analysis - Newser
Using data filters to optimize entry into Crinetics Pharmaceuticals Inc.Technical Screener for High Growth Stocks - Newser
Finanzdaten der Crinetics Pharmaceuticals Inc-Aktie (CRNX)
Umsatz
Nettogewinn
Free Cashflow
ENV
Crinetics Pharmaceuticals Inc-Aktie (CRNX) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Betz Stephen F. | Chief Scientific Officer |
Jun 12 '25 |
Sale |
32.23 |
97,483 |
3,141,877 |
99,713 |
0.10%
2.79%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):